Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
10 hedge funds and large institutions have $24.2M invested in Celyad Oncology SA American Depositary Shares in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
3,055% more capital invested
Capital invested by funds: $768K → $24.2M (+$23.5M)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
43% more funds holding
Funds holding: 7 → 10 (+3)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIG
Fortress Investment Group
New York
|
+$27.3M |
| 2 |
HF
HRT Financial
New York
|
+$160K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$74.7K |
| 4 |
Jane Street
New York
|
+$46.7K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$45.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$596K |
| 2 |
JP Morgan Chase
New York
|
-$12K |
| 3 |
Morgan Stanley
New York
|
-$3.62K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.41K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIG
1
Fortress Investment Group
New York
| $23.8M | +$27.3M | +6,500,000 | New |
|
|
HF
2
HRT Financial
New York
| $139K | +$160K | +38,105 | New |
|
|
3
Morgan Stanley
New York
| $88K | -$3.62K | -862 | -3% |
|
|
4
Wells Fargo
San Francisco,
California
| $69K | +$45.6K | +10,850 | +139% |
|
|
TSS
5
Two Sigma Securities
New York
| $65K | +$74.7K | +17,786 | New |
|
|
6
Jane Street
New York
| $44K | +$46.7K | +11,122 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $13K | -$3.41K | -812 | -18% |
|
8
National Bank of Canada
Montreal,
Quebec, Canada
| $12K | +$14.3K | +3,400 | New |
|
|
9
Osaic Holdings
Scottsdale,
Arizona
| $6K | -$1.6K | -380 | -20% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $4K | +$5.15K | +1,225 | New |
|
|
ECM
11
Endurant Capital Management
San Mateo,
California
| – | -$596K | -145,380 | Closed |
|
|
12
JP Morgan Chase
New York
| – | -$12K | -3,000 | Closed |
|
CYAD Hedge Fund Activity: Q4 2021 in Review
10 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q4 2021, worth a combined $24.2M — up 3,055% from $768K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CYAD positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Fortress Investment Group, opening a new position worth an estimated $27.3M. The largest seller was Endurant Capital Management, exiting entirely with an estimated $596K sold.
- 10 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q4 2021, up from 7 in Q3 2021.
- Funds reported $24.2M of Celyad Oncology SA American Depositary Shares stock for Q4 2021, up 3,055% quarter-over-quarter.
- 6 funds opened new Celyad Oncology SA American Depositary Shares positions in Q4 2021 and 3 closed out, a net change of +3 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q4 2021 was Fortress Investment Group, an estimated $27.3M added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q4 2021 was Endurant Capital Management, an estimated $596K sold.
Based on aggregated 13F filings for Q4 2021.